Poxel Announces Program Update and Preclinical Results on PXL770 for NASH Combinations and Other Metabolic Diseases

Poxel SA, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced new preclinical results for PXL770, the lead molecule in the Company’s adenosine monophosphate-activated protein kinase (AMPK) platform.